Showing results (221-230 of 324) with videos related to
Sort By:
Pageof 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2024
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung CancerDavid R Spigel, Afshin Dowlati, Yuanbin Chen, et al.British Journal of Cancer|April 4, 2024
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISIONTerufumi Kato, James Chih-Hsin Yang, Myung-Ju Ahn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2017
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerKaoru Kubota, Hiroshige Yoshioka, Fumihiro Oshita, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 9, 2016
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment RegimensLuis Paz-Ares, Vera Hirsh, Li Zhang, et al.Nature Communications|February 27, 2023
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trialJuliann Chmielecki, Tony Mok, Yi-Long Wu, et al.Cancer Medicine|December 23, 2023
Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancerYen-Ting Lin, Chao-Chi Ho, Wei-Hsun Hsu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 25, 2023
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 TrialMartin Reck, Fabrice Barlesi, James Chih-Hsin Yang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2023
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical TrialEdward B Garon, Shun Lu, Yasushi Goto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2018
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung CancerYi-Long Wu, Li Zhang, Dong-Wan Kim, et al.The Lancet. Respiratory Medicine|December 19, 2017
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic studyChia-Chi Lin, Jin-Yuan Shih, Chong-Jen Yu, et al.Pageof 33